Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT02895906
This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.
Looking for future studies?
Notify Me12 year–17 year
All sexes
Interventional
Phase 1
Philadelphia, Pennsylvania, 19104, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
Other names: NFC1
Time frame: Through study completion, up to 5 weeks
Time frame: Through study completion, up to 5 weeks
Time frame: Through study completion, up to 5 weeks
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05149898
22q11 Deletion Syndrome, 22q11.2 Deletion Syndrome
Greenville, South Carolina, United States
View Trial DetailsNCT04647500
22q11 Deletion Syndrome, 22q11.2 Deletion Syndrome
Geneva, Switzerland
View Trial DetailsNCT00916955
22q11 Deletion Syndrome, 22q11.2 Deletion Syndrome
Syracuse, New York, United States
View Trial DetailsNCT02460328
22q11 Deletion Syndrome, 22q11.2 Deletion Syndrome
Bangkoknoi, Bangkok, Thailand
View Trial Details